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Anti-tumour necrosis factor α therapy – Does it increase the risk of thyroid 
disease or protect against its development? 
Terapia z zastosowaniem przeciwciał przeciwko czynnikowi martwicy nowotworów α – zwiększa 
ryzyko chorób tarczycy czy chroni przed ich rozwojem?
Aleksandra Furtak, Anna Wedrychowicz, Jerzy Starzyk
Institute of Paediatrics, Department of Children and Youth Endocrinology, Jagiellonian University Medical 
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Abstract
Aim of the study: Tumour necrosis factor α (TNF-α) is a cytokine involved in the pathogenesis of many diseases, primarily those as-
sociated with autoimmunisation. Anti-TNF-α drugs are used in the therapy of many of them, such as rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis, psoriasis, or inflammatory bowel disease. TNF-α is also a key factor in the pathogenesis of autoim-
mune thyroid disease (AITD). The incidence of AITD in people with other autoimmune diseases is increased compared to the general 
population. Therefore, it would be interesting to find out if anti-TNF-α therapy of other autoimmune diseases could influence the 
possible development or regression of thyroid gland dysfunction, especially AITD. 
Aim of the study: The main aim of the study is to assess the effect of anti-TNF-α therapy used in inflammatory and immunological 
diseases on thyroid function and the development of AITD.
Conclusions: The real impact of anti-TNF-α therapy on the development of AITD remains an open question. The available studies 
concern the adult population; there are no data regarding this problem in children. Due to the increasing use of anti-TNF-α therapy 
also in the paediatric population, it seems reasonable to evaluate this subject in this group of patients.
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Streszczenie
Wprowadzenie: Czynnik martwicy nowotworów α (tumor necrosis factor α – TNF-α) to cytokina biorąca udział w patogenezie wielu 
chorób, przede wszystkim tych, które rozwijają się na podłożu autoimmunizacji. W terapii wielu z nich, takich jak reumatoidalne 
zapalenie stawów, łuszczycowe zapalenie stawów, zesztywniające zapalenie stawów kręgosłupa, łuszczyca czy nieswoiste choroby 
zapalne jelit, stosowane są leki określane mianem anty-TNF-α. Czynnik martwicy nowotworów α jest także kluczowym czynnikiem 
biorącym udział w patogenezie autoimmunizacyjnej choroby tarczycy. 
Częstość występowania autoimmunizacyjnej choroby tarczycy u osób chorujących  na wyżej wymienione choroby jest zwiększona 
w porównaniu z populacją ogólną. Stwarza to pytanie o wpływ terapii anty-TNF-α na ewentualny rozwój zaburzeń czynności i mor-
fologii gruczołu tarczowego, w tym szczególnie autoimmunizacyjnej choroby tarczycy.
Cel pracy: Głównym celem pracy jest ocena wpływu terapii anty-TNF-α, stosowanej w chorobach zapalnych i immunologicznych, 
na czynność tarczycy i rozwój autoimmunizacyjnej choroby tarczycy. 
Wnioski: Pytanie o wpływ terapii anty-TNF-α na rozwój autoimmunizacyjnej choroby tarczycy wciąż pozostaje bez konkretnej od-
powiedzi. Ponadto dostępne badania dotyczą populacji osób dorosłych. Z uwagi na coraz szersze zastosowanie terapii anty-TNF-α 
także w populacji pediatrycznej, zasadne wydaje się objęcie badaniami także tej grupy pacjentów.
Słowa kluczowe: 
TNF-α, terapia anty-TNF-α, autoimmunizacja, AITD.
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Introduction 
Tumour necrosis factor α is an important cytokine of inflam-
matory and immunological reactions, it is involved in the patho-
genesis of many diseases, including autoimmune diseases 
[1, 2]. This fact has become the basis for the search for new 
therapeutic options for patients suffering from diseases such as 
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, 
psoriasis, or inflammatory bowel diseases. Hence, anti-TNF-α 
drugs were created, the main task of which is to reduce the 
concentration of TNF-α and thereby inhibit the cascade of phe-
nomena occurring in the course of its action, which can lead 
to the development of the disease. TNF-α is also a key factor 
involved in the pathogenesis of thyroid disease, including AITD.
As is known from the available literature, the incidence of 
AITD in people with other autoimmune diseases, such as rheu-
matoid arthritis or inflammatory bowel disease, is increased 
compared to the general population. Therefore, it would be 
interesting to know if anti-TNF-α therapy of other autoimmune 
diseases could have an influence on possible development or 
regression of thyroid gland dysfunction, especially AITD.
Aim of the study
The main aim of the study is to assess the effect of anti-
TNF-α therapy used in inflammatory and autoimmunological 
diseases on thyroid function and the development of AITD.
Discussion
TNF-α, described for the first time by Carswell et al. in 1975, 
also known as cachectin, is an important cytokine of inflamma-
tory and immunological reactions [1, 2]. The TNF-α gene, locat-
ed on chromosome 6p21.3, consists of four exons, and its pro-
moter region shows very high variability, which determines the 
differentiated cytokine secretion in individuals [1]. Active TNF-α 
consists of three polypeptide chains, and it is formed as a result 
of a metalloproteinase (TNF-α-converting enzyme) action on its 
precursor synthesised as a  transmembrane protein. TNF-α is 
mainly produced by monocytes and macrophages. Its source 
can also be lymphocytes, mast cells, fibroblasts, keratinocytes, 
endothelial cells, cardiomyocytes, or thyroid cells [1, 3–5].
The main stimulators of TNF-α production are lipopolysac-
charides (LPS) of bacterial cell wall. In addition, TNF-α synthe-
sis is stimulated by other cytokines such as INF-α and IL-1. 
Also, TNF-α in an autocrine manner stimulates its own synthe-
sis. Glucocorticosteroids, IL-4, IL-10, and PGE2 are inhibitors of 
TNF-α production [1,6].
TNF-α has affinity for two types of receptors: TNF-R1 
(CD120a, p55 / 60) and TNF-R2 (CD120b, p75/80). They both, 
in their intracellular part, contain a  so-called death domain. 
TNF-R1 is activated by both free and transmembrane forms of 
TNF-α. TNF-R2 binds mainly to transmembrane forms of TNF-α. 
TNF-α receptors also differ in their location: TNF-R1 is located 
on nuclear cells, and TNF-R2 on immune cells, fibroblasts, and 
endothelial cells. In addition, expression of TNF-α receptors is 
increased by interleukin 1 (IL-1), interferon g (INF-g), IL-2, and 
TNF-α alone [1]. After binding of TNF-α to the TNF-R1 recep-
tor, the protein inhibitor SODD (silencer of death domain) is 
disconnected from the intracellular death domain, which allows 
activation of the TRADD protein (TNF-R-associated death do-
main) and further signal transduction steps. These stages can 
be carried out in three ways, depending on the connection of 
TRADD with subsequent relays. As a result of the attachment to 
the TNFR1-TRADD of the FADD (Fas-associated death domain) 
adapter protein, the caspase cascade (mainly 8, 3, 7) is activat-
ed, which ultimately leads to cell apoptosis [7]. As a result of the 
attachment to TNFR1-TRADD of RIP (receptor-interacting pro-
tein) and/or TRAF2 (TNF receptor-associated factor 2) transmit-
ters, a cascade of kinases is activated, including the kB inhibitor 
kinase (IkB), which is released by phosphorylation of IkB NF-kB 
cytoplasm, and its further activities at the level of the cell nucleus 
primarily lead to cell activation and prevent apoptosis [7]. The 
third way is through attachment to the TNFR1-TRADD of the 
TRAF2 adapter protein and the activation of the MEKK1 (Mito-
gen activated protein kinase/ERK kinase 1) system, which in-
duces the so-called JNK trail (c-Jun N-terminal kinase). The JNK 
pathway usually leads, through the transcription factor AP-1, 
to cell stimulation and proliferation. However, there is also evi-
dence of a proapoptotic effect of JNK pathway activation [8].
TNF-α is an extremely powerful mediator of inflammatory 
and immunological reactions. It can act independently or in 
combination with a wide range of other cytokines, affecting al-
most all cells in the body. TNF-α increases the cytotoxicity and 
phagocytic properties of cells of the immune system, it affects 
the proliferation and differentiation of B lymphocytes, T lympho-
cytes, and NK cells, and increases the synthesis of cytokines. 
In addition, it induces the expression of MHC I, MHC II, and 
adhesive particles and chemokines necessary for the accumu-
lation of immune cells at the site of inflammation [1].
The indisputable influence of TNF-α on the immune system 
makes it a key factor in the pathogenesis of many diseases, in-
cluding autoimmune diseases. This fact has become the basis 
for seeking new therapeutic options for patients suffering from 
diseases such as rheumatoid arthritis, psoriatic arthritis, anky-
losing spondylitis, psoriasis, or inflammatory bowel diseases. 
As a consequence of the knowledge of this phenomenon, anti-
TNF-α drugs were created, the main task of which is to directly 
reduce the concentration of TNF-α and thereby inhibit the cas-
cade of phenomena occurring in the course of its action.
TNF-α inhibitors are monoclonal antibodies, antibody frag-
ments, or fusion proteins. This group of biological drugs in-
cludes the following: infliximab (IFX), which is a  monoclonal, 
chimeric, human-mouse (75%: 25% protein structure) IgG1-
class antibody with a  molecular weight of 149 kDa; adalim-
umab (ADA), which is a  purely human class antibody; IgG1 
with a molecular weight of 148 kDa; certolizumab (CER), which 
is a humanised Fab fragment (approximately 90% human) of 
polyethylene glycol conjugated monoclonal antibody (PEG); 
and etanercept (ETA), which is a fusion protein composed of 
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the extracellular portion of the TNFR2/p75 receptor (this portion 
binds TNF-α) fused to the IgG1 Fc fragment [9].
TNF-α is also involved in the pathogenesis of thyroid 
dysfunction, including AITD. As many authors report, the 
concentration of TNF-α and TNF-α mRNA in the thyroid tis-
sue in people with AITD and other thyroid gland disorders is 
definitely higher compared to people without those disorders. 
Thyroid infiltrating lymphocytes are a reliable source of TNF-α; 
moreover, TNF-α production by thyroid cells alone has been 
reported. Zheng et al. [5] proved that thyroid cells are capable 
of producing TNF-α; Grubeck-Loebenstein et al. [10] did not 
show the presence of TNF-α mRNA in thyroid cells; and Diez 
et al. [4] showed an increased concentration of TNF-α in the 
thyroid tissue of people with AITD, but they did not specify 
its source (lymphocytes or thyreocytes). Thyroid cells have re-
ceptors for TNF-α on their surface, and it is postulated that 
TNF-α plays an essential role in cytotoxic mechanisms lead-
ing to the destruction of thyroid tissue in AITD [4]. This cyto-
kine is responsible for the increase in the expression of MHC 
class I molecules on thyroid cells in Graves’ disease and, to-
gether with INF-g, for the increase in MHC class II expression 
[11, 12]. TNF-α has been shown to increase IL-6 production 
by thyroid cells [13]. TNF-α affects the tightness of thyreo-
cyte epithelium, which leads to a  loss of its barrier function 
and an increase in the access of immune cells to intravesical 
antigens [14, 15]. In addition, TNF-α inhibits the production 
of thyroglobulin [16], reduces TSH-induced iodine uptake by 
thyroid cells [17], reduces type 2 deiodinase activity, which 
leads to a decrease in peripheral production of triiodothyro-
nine from thyroxine, and also reduces autocrine production of 
triiodothyronine in the thyroid alone [18,19]. TNF-α also influ-
ences the function of the hypothalamus-pituitary-thyroid axis. 
TNF-α inhibits TRH, which reduces the secretion of TSH [20]. 
The mechanisms described above are also involved in the 
pathogenesis of low T3 syndrome (euthyroid sick syndrome), 
which may accompany severe chronic diseases for which an 
increase in TNF-α is typical [20].
Due to the fact that diseases in which anti-TNF-α therapy 
is used are associated with a higher risk of developing AITD 
compared to the general population [21, 22] and that TNF-α 
plays a  role in the aetiopathogenesis of thyroid dysfunction, 
one would expect that anti-TNF-α therapy would have a protec-
tive effect against the possible development of AITD, and would 
be therapeutic if it is present.
There are few reports in the available literature about the de-
velopment of thyroid dysfunction during anti-TNF-α therapy. In 
addition, it provides very diverse data (Table I). Cerniglia et al. 
reported the development of hypothyroidism in a  47-year-old 
patient treated with infliximab for sarcoidosis. The ultrasound 
image of the thyroid gland corresponded to autoimmune thy-
roid disease. The authors postulated that the cause of AITD 
in the patient was the formation of autoantibodies (against inf-
liximab) that induced autoimmune thyroiditis [23]. Lahita et al. 
described a  55-year-old patient who developed autoimmune 
thyroiditis during long-term anti-TNF-α therapy for psoriatic ar-
thritis. Based on elevated TSH levels before starting anti-TNF-α 
therapy, the authors suggested that autoimmune thyroiditis may 
have occurred before treatment. Nonetheless, anti-TNF-α ther-
apy led to the progression of autoimmune thyroiditis [24]. Van 
Lieshout et al. are the authors of a report on the development 
of Graves’ disease in a patient treated with anti-TNF-α for rheu-
matoid arthritis [25]. Similarly, Allanore et al. reported a transient 
hyperthyroidism lasting one month in a patient after six months 
of treatment with etanercept [26]. Caramaschi et al. described 
a group of 54 patients with rheumatoid arthritis, among whom six 
changed the titre of anti-thyroid peroxidase antibodies (ATPO) 
or anti-thyroglobulin antibodies (aTG) from negative to positive, 
and four from positive to negative, after 12 months of therapy 
with infliximab or etanercept [27]. Atzeni et  al., in a  study of 
20 patients (including six with positive ATPO and eight with posi-
tive aTG) with rheumatoid arthritis, showed a change in ATPO 
from positive to negative in one of the patients after six months 
of treatment with adalimumab [28]. Pascart et al. examining pa-
tients treated with anti-TNF-α due to rheumatological diseases in 
their centre, described 11 cases of development of AITD, includ-
ing six cases of Graves’ disease, three cases of Hashimoto’s 
disease, and two cases of subacute thyroiditis [29]. Raterman 
et al., in a group of 138 patients with rheumatoid arthritis, after six 
months of treatment with adalimumab, described a change in 
the ATPO titre from positive to negative in one of 21 patients with 
a positive ATPO at baseline. They also indicated a lower average 
ATPO concentration after therapy (267 to 201 IU/ml). In addi-
tion, two patients with hypothyroidism reported a return to euthy-
roidism. They also showed a decrease in TSH (from 12.5 mU/l 
[6.7–18.4] to 7.1 mU/l [4.9–13.8]) in patients with hypothyreosis, 
who were ATPO positive and not receiving levothyroxine [30]. 
Elkayam et al., in a study group of 26 patients with rheumatoid 
arthritis, described a negative ATPO titre in all patients before 
and after 14 weeks of treatment with infliximab [31]. Tarhan et al., 
in a study of 108 patients with ankylosing arthritis spine (44 re-
ceived anti-TNF-α, 64 received other drugs), reported a positive 
ATPO titre in 23 patients not treated with anti-TNF-α (mean ATPO 
86.69 ± 65.28 U/ml), compared to nine patients receiving anti-
TNF-α (mean TPO 36.61 ±14.02 U/ml) [32]. Paschou et al. stud-
ied a group of 41 patients (18 treated with anti-TNF-α, 12 treated 
with other drugs followed by anti-TNF-α, 11 treated only with 
other drugs) with Crohn’s disease or ulcerative enteritis. They 
found overt or subclinical hyperthyroidism in two patients in the 
untreated anti-TNF-α group and no thyroid dysfunction or AITD 
in patients receiving anti-TNF-α. In addition, they showed the 
presence of thyroid antibodies in 5.6% of patients treated with 
anti-TNF-α and in 17.4% of those treated with other drugs [33].
Analysing the impact of anti-TNF-α therapy on thyroid func-
tion and the development of autoimmune thyroid disease, it is 
also worth paying attention to the role of TNF-α and anti-TNF-α 
therapy in thyroid-associated ophthalmopathy (TAO). Accord-
ing to the data, TNF-α is involved in the pathogenesis of TAO 
[34]. For this reason, anti-TNF-α therapy is increasingly being 
used to treat TAO. Paridaens et al., in their pilot study, present-
ed 10 patients with mild to moderate Graves’ ophthalmopathy 
treated with etanercept for 12 weeks. In this study, 60% of pa-
tients had moderate to marked improvement of TAO after this 
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Table I. Effect of anti-TNF-α therapy on thyroid function – summary of available publications
The negative effect of anti-TNF-α 
therapy used in inflammatory and 
immunological diseases on thyroid 
function and the development of AITD
The positive effect of anti-TNF-α therapy 
used in inflammatory and immunological 
diseases on thyroid function and the 
development of AITD
The neutral effect of anti-TNF-α 
therapy used in inflammatory 
and immunological diseases 
on thyroid function and the 
development of AITD
Cerniglia et al. 2013 [23]
development of hypothyroidism in 
a 47-year-old patient treated with anti-
TNF-α therapy for sarcoidosis
Caramaschi et al. 2006 [27]
changed the titre of ATPO or aTG from 
positive to negative, after 12 months of 
therapy with anti TNF-α for rheumatoid arthritis 
in four patients from group of 54 patients 
Elkayam et al. 2005 [31]
negative ATPO titre in all 
26 patients before and after 
14 weeks of treatment with anti-
TNF-α for rheumatoid arthritis
Lahita et al. 2011 [24]
progression of autoimmune thyroiditis in 
a 55-year-old patient during long-term 
anti-TNF-α therapy for psoriatic arthritis
Raterman et al. 2011 [30] 
change in the ATPO titre from positive to 
negative in one of 21 patients in a group of 
138 patients with rheumatoid arthritis after 
6 months of treatment with anti TNF-α
lower average ATPO concentration after 
therapy (267 to 201 IU/ml)
two patients with hypothyroidism reported 
a return to euthyroidism
decrease in TSH (from 12.5 mU/l (6.7–18.4) 
to 7.1 mU/l [4.9–13.8]) in patients with 
hypothyreosis, ATPO positive, and not 
receiving levothyroxine
Van Lieshout et al. 2008 [25]
development of Graves’ disease in 
a patient treated with anti TNF-α for 
rheumatoid arthritis
Tarhan et al. 2013 [32] 
positive ATPO titre in 9 patients receiving 
anti-TNF-α (mean ATPO 36.61 ±14.02 U/ml) 
compared to 23 patients not treated with anti 
TNF-α (mean ATPO 86.69 ±65.28 U/ml) due 
to ankylosing arthritis spine (44 received anti-
TNF-α, 64 other drugs)  
Allanore et al. 2001 [26]
development of transient 
hyperthyroidism in a patient treated with 
anti-TNF-α for rheumatoid arthritis 
Paschou et al. 2018 [33]
no thyroid dysfunction or AITD in patients 
receiving anti-TNF-α compared to development 
overt or subclinical hyperthyroidism in two 
patients in the untreated anti-TNF-α group 
of 41 patients (18 treated with anti TNF-α; 
12 treated with other drugs followed by anti 
TNF-α; 11 treated only with other drugs) with 
Crohn’s disease or ulcerative enteritis
presence of thyroid antibodies in 5.6% of 
patients treated with anti-TNF-α and in 17.4% 
treated with other drugs. 
Caramaschi et al. 2006 [27]
changed the titre of ATPO or aTG from 
negative to positive, after 12 months of 
therapy with anti-TNF-α for rheumatoid 
arthritis in 6 patients from a group of 
54 patients 
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treatment [35]. Boskovic et al. presented a female patient with 
both Graves’ ophthalmopathy and rheumatoid arthritis, who 
was treated with etanercept. This treatment led to an improve-
ment of eye symptoms [36]. Komorowski et al. found a positive 
effect of Infliximab administration on active TAO in a 58-year-
old woman with Graves’ disease [37]. These findings suggest 
that anti-TNF-α therapy may benefit patients with TAO, but all of 
the mentioned authors point out the necessity of larger studies 
to confirm its efficacy and safety [38]. 
Conclusions
Research on biological anti-TNF-α drugs dates back to the 
1990s. According to the cited data, despite the relatively long 
observation time, the question about the impact of anti-TNF-α 
therapy on the development or regression of AITD remains 
open. In addition, according to our knowledge, all available 
studies concern the adult population. Due to the increasing 
use of anti-TNF-α therapy also in the paediatric population, it 
seems reasonable to evaluate this group of patients regarding 
this subject.
In our clinical centre, anti-TNF-α treatment of children and 
adolescents with inflammatory bowel diseases is carried out. 
We are currently in the process of investigating the effect of 
anti-TNF-α therapy on thyroid gland function and morphology 
in children and adolescents with Crohn’s disease treated with 
infliximab. The first preliminary results are promising. They in-
dicate that anti-TNF-α treatment may reduce the incidence of 
AITD in paediatric patients with Crohn’s disease compared to 
non-biological patients. 
Table I. Effect of anti-TNF-α therapy on thyroid function – summary of available publications (cont.)
The negative effect of anti-TNF-α 
therapy used in inflammatory and 
immunological diseases on thyroid 
function and the development of AITD
The positive effect of anti-TNF-α therapy 
used in inflammatory and immunological 
diseases on thyroid function and the 
development of AITD
The neutral effect of anti-TNF-α 
therapy used in inflammatory 
and immunological diseases 
on thyroid function and the 
development of AITD
Pascart et al. 2014 [29]
development of thyroid diseases in 11 
patients (six cases of Graves’ disease, 
three cases of Hashimoto’s disease and 
two cases of subacute thyroiditis) treated 
with anti-TNF-α due to rheumatological 
diseases
anti-TNF-α – anti-tumour necrosis factor α; AITD – autoimmune thyroid disease; ATPO – anti-thyroid peroxidase antibodies; aTG – anti-thyro-
globulin antibodies; TSH – thyroid-stimulating hormone
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